Esperion Team

Esperion combines excellence in science with superior business skills to deliver innovative therapies for improving cardiovascular and metabolic health. This is possible only through the considerable experience, expertise, and commitment of our exceptional leaders and colleagues. We also have deep and broad relationships with other industry-leading experts and businesses, enabling us to extend our impact where and when needed. We know what is required for success and how to achieve it.

  • Tim Mayleben

    President and Chief Executive Officer

    Tim Mayleben is President and Chief Executive Officer and has been a member of our board of directors since February 2010. Prior to joining Esperion, Tim was President, CEO and a Director of Aastrom Biosciences, Inc. (NASDAQ: ASTM). Previously, Tim was President, Chief Operating Officer and a director of NightHawk Radiology Holdings, Inc. Prior to joining Nighthawk, Tim was the COO of the original Esperion, until its acquisition by Pfizer in 2004. Tim is an advisor to, investor in, and member of the board of directors of several life science companies, including DeNovo Sciences, Kaléo Pharma, Lycera Corporation and Marinus Pharmaceuticals. Tim earned an MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BBA from the University of Michigan, Ross School of Business.

  • Roger Newton, PhD, FAHA

    Executive Chairman and Chief Scientific Officer

    Roger Newton, PhD, FAHA, is founder, Executive Chairman and Chief Scientific Officer of Esperion and is a fellow of the American Heart Association. Prior to founding Esperion in 2008, Roger was Senior Vice President, Pfizer Global R&D from 2004 to 2008. Previously, Roger was Co-founder, President & CEO of the original Esperion from July 1998 until its acquisition by Pfizer in 2004. Prior to founding the original Esperion, Roger was Chairman of the Atherosclerosis Drug Discovery Team at Warner Lambert from 1981 to 1998. Roger is a director of a number of life science companies including Juventas Therapeutics, Inc. and Rubicon Genomics, Inc. and is also a member of the Technology Advisory Boards for Arboretum Ventures and Metagenics, Inc. Roger earned a Ph.D. in Nutrition from the University of California, Davis, an M.S. in Nutritional Biochemistry from the University of Connecticut, and a B.S. in Biology from Lafayette College.

  • Marianne Andreach

    Vice President, Strategic Marketing and Product Planning

    Marianne Andreach is Vice President of Strategic Marketing and Product Planning. Prior to joining Esperion, Marianne was a consultant in the pharmaceutical industry. Previously, she was Senior Director, Business Development and Team Lead, MDCO-216 (ApoA-I Milano) at The Medicines Company. Marianne also worked in Medical Affairs at Pfizer Global R&D, and led Marketing and Product Planning at the original Esperion Therapeutics. Additionally, Marianne has worked in a variety of marketing and product planning roles at Bristol-Myers Squibb and Parke-Davis, including working on the launch teams for both Pravachol and Lipitor, as well as supporting both Plavix and Glucophage. Marianne earned a BA in Biology/History from the College of the Holy Cross.

  • Keith Lenden

    Vice President, Corporate Development and Strategy

    Keith Lenden is Vice President of Corporate Development and Strategy. Prior to joining Esperion, Keith was Vice President, Product & Business Development at Maxygen and was a co-founder of Receptos (NASDAQ: RCPT) and Abide Therapeutics. Keith started his career in biotechnology at LEK Consulting, is a Kauffman Fellow, earned an MBA from UC Berkeley’s Haas School of Business and studied engineering at Dartmouth College’s Thayer School.